Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerabili...
How does this data update affect the probability of success for future Phase 3 trials and overall portfolio risk?
What are the potential reimbursement and commercial launch timelines if the data support further development?
How might the Phase 2 results influence the company's cash burn rate and need for additional financing?
11 days ago